Microbiology and Treatment of Diabetic Foot Infection

  • Mary T. LaSalvia
  • Adolf W. KarchmerEmail author
Part of the Contemporary Diabetes book series (CDI)


The foot of patients with diabetes mellitus is affected by several processes which not only contribute to the development and progression of infection but on occasion alter the appearance of the foot in ways that may obscure the clinical features of local infection. Neuropathy involving the motor fibers supplying muscles of the foot causes asymmetric muscle strength, which in turn results in foot deformities and maldistribution of weight (or pressure) on the foot surface. Dysfunction of the sensory fibers supplying the skin and deeper structural elements of the foot allows minor and major injury to these tissues to proceed without appreciation by the patient. As a result of neuropathy, the foot may be dramatically deformed, ulcerate in areas of unperceived trauma (mal perforans), and on occasion be warm and hyperemic in response to deep structural injury (acute Charcot’s disease). This warmth and hyperemia may be misinterpreted as cellulitis and an ulceration, while a major portal of entry for infection, may be uninfected. In the patient with diabetes, peripheral neuropathy may develop in isolation or commonly in parallel with atherosclerotic peripheral vascular disease. The latter involves major inflow vessels to the lower extremity but commonly is associated with occlusive lesions of the tibial and peroneal arteries between the knee and ankle. The resulting arterial insufficiency can alter the appearance of the foot and obscure infection. Rubor may reflect vascular insufficiency rather than inflammation and conversely pallor may mute the erythema of acute infection. Gangrene and necrosis may be primarily ischemic or may reflect accelerated ischemia in the setting of infection. In sum, the diagnosis of infection involving the foot in patients with diabetes requires a careful detailed examination of the lower extremity and its blood supply.


Diabetic foot ulcers Foot infection Foot osteomyelitis Antibiotic therapy for diabetic foot infection Diagnosis foot osteomyelitis 


  1. 1.
    Lipsky BA, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e132–73.PubMedCrossRefGoogle Scholar
  2. 2.
    Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev. 2004;20(Suppl 1):S68–77.PubMedCrossRefGoogle Scholar
  3. 3.
    Lavery LA, et al. Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006;29(6):1288–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Peters EJ, Lavery LA, Armstrong DG. Diabetic lower extremity infection: influence of physical, psychological, and social factors. J Diabetes Complications. 2005;19(2):107–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Newman LG, et al. Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA. 1991;266(9):1246–51.PubMedCrossRefGoogle Scholar
  6. 6.
    Grayson ML, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994;18(5):683–93.PubMedCrossRefGoogle Scholar
  7. 7.
    Karchmer AW, Gibbons GW. Foot infections in diabetes: evaluation and management. In: Remington JS, Swartz MN, editors. Current clinical topics in infectious diseases. Boston: Blackwell Scientific Publications; 1994. p. 1–22.Google Scholar
  8. 8.
    Pittet D, et al. Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up. Arch Intern Med. 1999;159(8):851–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Williams DT, Hilton JR, Harding KG. Diagnosing foot infection in diabetes. Clin Infect Dis. 2004;39(Suppl 2):S83–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Armstrong DG, et al. Leukocytosis is a poor indicator of acute osteomyelitis of the foot in diabetes mellitus. J Foot Ankle Surg. 1996;35(4):280–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Jeandrot A, et al. Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study. Diabetologia. 2008;51(2):347–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Butalia S, et al. Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA. 2008;299(7):806–13.PubMedCrossRefGoogle Scholar
  13. 13.
    Hingorani A, et al. The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63(2 Suppl):3S–21S.PubMedCrossRefGoogle Scholar
  14. 14.
    Grayson ML, et al. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA. 1995;273(9):721–3.PubMedCrossRefGoogle Scholar
  15. 15.
    Morales Lozano R, et al. Validating the probe-to-bone test and other tests for diagnosing chronic osteomyelitis in the diabetic foot. Diabetes Care. 2010;33(10):2140–5.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Lam K, et al. Diagnostic accuracy of probe to bone to detect osteomyelitis in the diabetic foot: a systematic review. Clin Infect Dis. 2016;63:944.PubMedCrossRefGoogle Scholar
  17. 17.
    Alvaro-Afonso FJ, et al. Inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography. Diabetes Res Clin Pract. 2014;105(1):e3–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Jeffcoate WJ, Lipsky BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis. 2004;39(Suppl 2):S115–22.PubMedCrossRefGoogle Scholar
  19. 19.
    Weiner RD, et al. Histology versus microbiology for accuracy in identification of osteomyelitis in the diabetic foot. J Foot Ankle Surg. 2011;50(2):197–200.PubMedCrossRefGoogle Scholar
  20. 20.
    Senneville E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis. 2006;42(1):57–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Wagner FW. The diabetic foot and amputation of the foot. In: Mann RA, editor. Sugery of the foot. St. Louis: C.V. Mosby; 1986. p. 421–55.Google Scholar
  22. 22.
    Lavery LA, et al. Validation of the Infectious Diseases Society of America’s diabetic foot infection classification system. Clin Infect Dis. 2007;44(4):562–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev. 2004;20(Suppl 1):S90–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Lipsky BA, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39(7):885–910.PubMedCrossRefGoogle Scholar
  25. 25.
    Sapico FL, et al. Quantitative aerobic and anaerobic bacteriology of infected diabetic feet. J Clin Microbiol. 1980;12(3):413–20.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Slater RA, et al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med. 2004;21(7):705–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Pellizzer G, et al. Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet Med. 2001;18(10):822–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis. 2004;39(Suppl 2):S104–14.PubMedCrossRefGoogle Scholar
  29. 29.
    Lipsky BA, et al. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med. 1990;150(4):790–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot. Soft tissue and bone infection. Infect Dis Clin N Am. 1990;4(3):409–32.Google Scholar
  31. 31.
    Caputo GM, Ulbrecht JS, Cavanagh PR, Juliano PJ. The role of cultures in mild diabetic foot cellulitis. Infect Dis Clin Pract. 2000;9:241–3.CrossRefGoogle Scholar
  32. 32.
    Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol. 1999;26(3–4):267–76.PubMedCrossRefGoogle Scholar
  33. 33.
    Lipsky BA, et al. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia. 2010;53(5):914–23.PubMedCrossRefGoogle Scholar
  34. 34.
    Dang CN, et al. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med. 2003;20(2):159–61.PubMedCrossRefGoogle Scholar
  35. 35.
    Tentolouris N, et al. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med. 1999;16(9):767–71.PubMedCrossRefGoogle Scholar
  36. 36.
    Yates C, et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care. 2009;32(10):1907–9.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Kandemir O, et al. Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. J Infect. 2007;54(5):439–45.PubMedCrossRefGoogle Scholar
  38. 38.
    Scher KS, Steele FJ. The septic foot in patients with diabetes. Surgery. 1988;104(4):661–6.PubMedGoogle Scholar
  39. 39.
    Citron DM, et al. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007;45(9):2819–28.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Gadepalli R, et al. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care. 2006;29(8):1727–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Gerding DN. Foot infections in diabetic patients: the role of anaerobes. Clin Infect Dis. 1995;20(Suppl 2):S283–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Johnson S, et al. Use of an anaerobic collection and transport swab device to recover anaerobic bacteria from infected foot ulcers in diabetics. Clin Infect Dis. 1995;20(Suppl 2):S289–90.PubMedCrossRefGoogle Scholar
  43. 43.
    Hartemann-Heurtier A, et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet Med. 2004;21(7):710–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Richard JL, et al. Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabetes Metab. 2008;34(4 Pt 1):363–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Liu C, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–92.PubMedCrossRefGoogle Scholar
  46. 46.
    Hatipoglu M, et al. Causative pathogens and antibiotic resistance in diabetic foot infections: a prospective multi-center study. J Diabetes Complicat. 2016;30(5):910–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Sugandhi P, Prasanth DA. Microbiological profile of bacterial pathogens from diabetic foot infections in tertiary care hospitals, Salem. Diabetes Metab Syndr. 2014;8(3):129–32.PubMedCrossRefGoogle Scholar
  48. 48.
    Lipsky BA, et al. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis. 1997;24(4):643–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Caputo GM, et al. Assessment and management of foot disease in patients with diabetes. N Engl J Med. 1994;331(13):854–60.PubMedCrossRefGoogle Scholar
  50. 50.
    Board NDA. The national long-range plan to combat diabetes. Washington: US Government Printing Office; 1987.Google Scholar
  51. 51.
    Association, A.D. Consensus development conference of diabetic foot wound care. Diab Care. 1999;22:1354–60.CrossRefGoogle Scholar
  52. 52.
    Tan JS, et al. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis. 1996;23(2):286–91.PubMedCrossRefGoogle Scholar
  53. 53.
    van Baal JG. Surgical treatment of the infected diabetic foot. Clin Infect Dis. 2004;39(Suppl 2):S123–8.PubMedCrossRefGoogle Scholar
  54. 54.
    McIntyre KE Jr, et al. Guillotine amputation in the treatment of nonsalvageable lower-extremity infections. Arch Surg. 1984;119(4):450–3.PubMedCrossRefGoogle Scholar
  55. 55.
    Chantelau E, et al. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabet Med. 1996;13(2):156–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Jones EW, Edwards R, Finch R, Jaffcoate WJ. A microbiologic study of diabetic foot lesions. Diab Med. 1984;2:213–5.CrossRefGoogle Scholar
  57. 57.
    Lipsky BA, McDonald D, Litka PA. Treatment of infected diabetic foot ulcers: topical MSI-78 vs. oral ofloxacin. Diabetologia. 1997;40(Suppl 1):482.Google Scholar
  58. 58.
    Fox HR, Karchmer AW. Management of diabetic foot infections, including the use of home intravenous antibiotic therapy. Clin Podiatr Med Surg. 1996;13(4):671–82.PubMedGoogle Scholar
  59. 59.
    Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis. 2004;38(1):17–24.PubMedCrossRefGoogle Scholar
  60. 60.
    Stevens DL, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34(11):1481–90.PubMedCrossRefGoogle Scholar
  61. 61.
    Arbeit RD, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673–81.PubMedCrossRefGoogle Scholar
  62. 62.
    Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55(2):240–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Stryjewski ME, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46(11):1683–93.PubMedCrossRefGoogle Scholar
  64. 64.
    Wilcox MH, et al. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv53–65.PubMedGoogle Scholar
  65. 65.
    Corey GR, et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv41–51.PubMedGoogle Scholar
  66. 66.
    Lipsky BA, et al. Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience. Diabetes Metab Res Rev. 2015;31(4):395–401.PubMedCrossRefGoogle Scholar
  67. 67.
    Selva Olid A, et al. Systemic antibiotics for treating diabetic foot infections. Cochrane Database Syst Rev. 2015;9:CD009061.Google Scholar
  68. 68.
    Crouzet J, et al. Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy. Int J Infect Dis. 2011;15(9):e601–10.PubMedCrossRefGoogle Scholar
  69. 69.
    Lipsky BA. Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection? Clin Microbiol Infect. 2007;13(4):351–3.PubMedCrossRefGoogle Scholar
  70. 70.
    Beam T, Gutierrez I, Powell S, et al. Prospective study of the efficacy and safety of oral and intravenous ciprofloxacin in the treatment of diabetic foot infections. Rev Infect Dis. 1989;11(Suppl 5):S1163.Google Scholar
  71. 71.
    Hughes CE, et al. Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime. Clin Ther. 1987;10(Suppl A):36–49.PubMedGoogle Scholar
  72. 72.
    Peterson LR, et al. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med. 1989;86(6 Pt 2):801–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Lipsky BA, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. 2005;366(9498):1695–703.PubMedCrossRefGoogle Scholar
  74. 74.
    Lipsky BA, et al. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother. 2007;60(2):370–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Vick-Fragoso R, et al. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection. 2009;37(5):407–17.PubMedCrossRefGoogle Scholar
  76. 76.
    Schaper NC, et al. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection. 2013;41(1):175–86.PubMedCrossRefGoogle Scholar
  77. 77.
    Xu ZR, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial. J Antimicrob Chemother. 2016;71(6):1688–96.PubMedCrossRefGoogle Scholar
  78. 78.
    Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res Clin Pract. 2008;80(3):344–51.PubMedCrossRefGoogle Scholar
  79. 79.
    Lauf L, et al. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagn Microbiol Infect Dis. 2014;78(4):469–80.PubMedCrossRefGoogle Scholar
  80. 80.
    Cooper G, Platt R. Staphylococcus aureus bacteremia in diabetic patients. Endocarditis and mortality. Am J Med. 1982;73(5):658–62.PubMedCrossRefGoogle Scholar
  81. 81.
    Bamberger DM, Daus GP, Gerding DN. Osteomyelitis in the feet of diabetic patients. Long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. Am J Med. 1987;83(4):653–60.PubMedCrossRefGoogle Scholar
  82. 82.
    Game FL, Jeffcoate WJ. Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia. 2008;51(6):962–7.PubMedCrossRefGoogle Scholar
  83. 83.
    Senneville E, et al. Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care. 2008;31(4):637–42.PubMedCrossRefGoogle Scholar
  84. 84.
    Senneville E, et al. Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother. 2001;48(6):927–30.PubMedCrossRefGoogle Scholar
  85. 85.
    Ha Van G, et al. Treatment of osteomyelitis in the diabetic foot. Contribution of conservative surgery. Diabetes Care. 1996;19(11):1257–60.PubMedCrossRefGoogle Scholar
  86. 86.
    Berendt AR, et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. 2008;24(Suppl 1):S145–61.PubMedCrossRefGoogle Scholar
  87. 87.
    Acharya S, et al. Conservative management of diabetic foot osteomyelitis. Diabetes Res Clin Pract. 2013;101(3):e18–20.PubMedCrossRefGoogle Scholar
  88. 88.
    Lazaro-Martinez JL, Aragon-Sanchez J, Garcia-Morales E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial. Diabetes Care. 2014;37(3):789–95.PubMedCrossRefGoogle Scholar
  89. 89.
    Lesens O, et al. Staphylococcus aureus-related diabetic osteomyelitis: medical or surgical management? A French and Spanish retrospective cohort. Int J Low Extrem Wounds. 2015;14(3):284–90.PubMedCrossRefGoogle Scholar
  90. 90.
    Tone A, et al. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care 2015;38:302–307. Diabetes Care. 2015;38(4):735.PubMedGoogle Scholar
  91. 91.
    Berendt AR, et al. Specific guidelines for treatment of diabetic foot osteomyelitis. Diabetes Metab Res Rev. 2008;24(Suppl 1):S190–1.PubMedCrossRefGoogle Scholar
  92. 92.
    Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis. 1997;25(6):1318–26.PubMedCrossRefGoogle Scholar
  93. 93.
    Eneroth M, van Houtum WH. The value of debridement and vacuum-assisted closure (V.A.C.) therapy in diabetic foot ulcers. Diabetes Metab Res Rev. 2008;24(Suppl 1):S76–80.PubMedCrossRefGoogle Scholar
  94. 94.
    Chen S, Giurini JM, Karchmer AW. Invasive systemic infection following hospital treatment for diabetic foot ulcer: risk of occurrence and effect on mortality. Boston: Beth Israel Deaconess Medical Center; 2016.Google Scholar
  95. 95.
    Gibbons GW, Eliopoulos GM. Infections of the diabetic foot. In: Kozak GP, Hoar Jr CS, Rowbotham RL, editors. Management of diabetic foot problems. Philadelphia: Saunders; 1984. p. 97–102.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Infectious DiseasesBeth Israel Deaconess Medical CenterBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA

Personalised recommendations